Traitement hormonal chez les femmes ménopausées: tous les traitements sont-ils équivalents?

Ribot, C.; Tremollieres, F.

doi:10.1016/j.gyobfe.2007.02.013

Cited by 9 publications

(5 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, MHTs are still prescribed nowadays, mostly in case of severe climacteric symptoms . A wide range of MHTs, composed of opposed or unopposed estrogens with a progestogen, have been marketed, particularly in France where a large variety of progestogens is available …”

Section: Introductionmentioning

confidence: 99%

“…22 A wide range of MHTs, composed of opposed or unopposed estrogens with a progestogen, have been marketed, particularly in France where a large variety of progestogens is available. [23][24][25] The association between MHT use and melanoma risk in women has yielded inconsistent results in the epidemiologic literature. A meta-analysis of 10 observational studies published between 1983 and 2009 failed to find a statistically significant association.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study

Cervenka

Rahmoun

Mahamat‐Saleh

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Cutaneous melanoma has been suspected to be influenced by female hormones. Several studies reported a positive association between menopausal hormone therapy (MHT) use and melanoma risk; however, previous findings were conflicting. We sought to explore the associations between MHT use and melanoma risk in a prospective cohort of women in France, where a particularly wide variety of MHT formulations are available. E3N is a prospective cohort of 98,995 French women aged 40–65 years in 1990. MHT use was assessed through biennial self‐administered questionnaires. We used Cox proportional hazards regression models adjusted for age and skin cancer risk factors. Over 1990–2008, 444 melanoma cases were ascertained among 75,523 postmenopausal women. Ever use of MHT was associated with a higher melanoma risk (hazard ratio (HR) = 1.35, 95% confidence intervals (CI) = 1.07–1.71). The association was strongest among past users (HR = 1.55, CI = 1.17–2.07, homogeneity for past vs. recent use: p = 0.11), and users of MHT containing norpregnane derivatives (HR = 1.59, CI = 1.11–2.27), although with no heterogeneity across types of MHT (p = 0.13). Among MHT users, the association was similar across durations of use. However, a higher risk was observed when treatment onset occurred shortly after menopause (<6 months: HR = 1.55, CI = 1.16–2.07 vs. ≥2 years). Associations between MHT use and melanoma risk were similar after adjustment for UV exposure, although MHT users were more likely to report sunscreen use than nonusers. Our data do not support a strong association between MHT use and melanoma risk. Further investigation is needed to explore potential effect modification by UV exposure on this relationship.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study

Cervenka

Rahmoun

Mahamat‐Saleh

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Ce glissement sémantique est critiquable, un nouveau mot en apparence salvateur n'est pas un nouveau concept et surtout, fait comme si tous les traitements hormonaux étaient les mêmes. Le terme de THS devrait s'appliquer aux traitements utilisant des hormones bio-identiques, 17ß-estradiol et progestérone, administrées dans des conditions les plus proches possible de la physiologie, de façon cyclique et plutô t par voie parentérale [1]. Tout ce qui n'est pas un THS ainsi défini sortirait de la boîte de Pandore du THM.…”

Section: Introductionunclassified

Contre la médicalisation de la ménopause avec le THM

Guyot

2008

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…A follow-up of woman is necessary during this period in order to avoid complications and the occurrence of other diseases such as cardiovascular diseases, diabetes, joint and met abolic diseases (Tillier, 2005). Modern medical care is based on hormonal menopause treatments (THM) that eliminate certain symptoms (Ribot and Tremollieres, 2007). However, the use of these hormones to replac e those naturally secreted by the ovaries often causes potentially serious side effects such as breast cancer, osteoporosis, heart diseas e including heart attacks and strokes, which are currently the leading cause of death in the world (Fournier et al, 2003;Azoulay, 2004).…”

mentioning

confidence: 99%

Menopause disorders and their treatment in traditional medicine in Burkina Faso

Ramde-Tiendrebeogo¹,

Hien²,

Millogo-Koné³

et al. 2019

J. Med. Plants Res.

View full text Add to dashboard Cite

A survey was conducted in the central region of Burkina Faso to find out about women's menopauserelated disorders and their treatment in traditional medicine. Fifty-six (56) specie s have been identified to treat different symptom s such a s hot fla she s, insomnia, nausea, joint and muscle pain, itching, lower abdominal pain, edema, mood disorders, vertigo. Leaves and stem bark were the most recommended in the preparation of recipes, at 43 and 39% re spectively. The majority of the specie s (60.72%) was local food plants with a high use value (UV s ≥ 0.50).

show abstract

Traitement hormonal chez les femmes ménopausées: tous les traitements sont-ils équivalents?

Cited by 9 publications

References 75 publications

Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study

Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study

Contre la médicalisation de la ménopause avec le THM

Menopause disorders and their treatment in traditional medicine in Burkina Faso

Contact Info

Product

Resources

About